# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Under the terms of the Letter of Intent, Entero Therapeutics, upon execution of a definitive agreement, would receive an exclus...
- SEC Filing
Entero Therapeutics, Inc. ("Entero" or the "Company") (NASDAQ:ENTO), a clinical-stage biopharmaceutical company...
Entero Therapeutics, Inc., (NASDAQ:ENTO), ("Entero Therapeutics" or the "Company"), a clinical-stage biopharmac...